Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 8/20 | 0.47 |
| ▸ | CA2 | P00918 | 8/20 | 0.47 |
| ▸ | CA12 | O43570 | 7/20 | 0.47 |
| ▸ | CA4 | P22748 | 7/20 | 0.47 |
| ▸ | CA7 | P43166 | 7/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.47 |
| ▸ | CA3 | P07451 | 6/20 | 0.47 |
| ▸ | CA6 | P23280 | 6/20 | 0.47 |
| ▸ | CA5A | P35218 | 6/20 | 0.47 |
| ▸ | CA9 | Q16790 | 6/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 6/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 9/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818581 | 0.85 | MEN1 (0.53) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2972696 | 0.85 | MEN1 (0.53) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL3818576 | 0.85 | MEN1 (0.53) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2979260 | 0.85 | MEN1 (0.53) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL2972692 | 0.85 | TP53 (0.55) | MEN1KMT2ACA1CA2CA12 | |
| Bromide SCHEMBL2979903 | 0.84 | MEN1 (0.52) | MEN1KMT2ACA1CA2CA12 | |
| Bromide SCHEMBL2979901 | 0.84 | MEN1 (0.52) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL13204754 | 0.83 | MEN1 (0.51) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL13204756 | 0.83 | MEN1 (0.51) | MEN1KMT2ACA1CA2CA12 | |
| SCHEMBL6700861 | 0.82 | MEN1 (0.42) | MEN1KMT2ACA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772260-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772260-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772260-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7741349-B2 | Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-7741349-B2 | Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-7741349-B2 | Imidazo[2, 1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-06-22 | — | — | US | disclosed |
| US-7714003-B2 | Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-7714003-B2 | Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-7714003-B2 | Imidazo[2,1-b ]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-05-11 | — | — | US | disclosed |
| US-7700635-B2 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS INC. (CA) | 2010-04-20 | — | — | US | disclosed |
| US-7230019-B2 | Imidazo [2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-06-12 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-04-19 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | AEGERA THERAPEUTICS, INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | PHARMASCIENCE INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| US-20050069492-A1 | Imidazo [2,1-b]-1,3,4-thiadiazole suflonamides | PHARMASCIENCE INC. (CA) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021476-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA1 748/4885 |
| US-20070021416-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA1 748/4885 |
| US-20070088059-A1 | Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides | SMN1; SMN2, PMP22, BDNF | MEN1 3572/4885KMT2A 3862/4885CA1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.